PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma
Patients with WHO grade II/III recurrent meningioma experienced clinically meaningful efficacy with 177Lutetium-Dotatate.
Patients with WHO grade II/III recurrent meningioma experienced clinically meaningful efficacy with 177Lutetium-Dotatate.
Medical experts analyze the exploratory efficacy and safety results for patients with portal vein invasion (Vp4), addressing the challenges in treating this subgroup.
Drs Armstrong and Tawagi discuss the board review plans they followed in the months leading up to their hematology and oncology board exams.
The role of B cells in cancer remains incompletely understood. Three recent publications, including a study by Fitzsimons et al. in this issue of Cancer Cell,…
PURPOSEWe examined the trends in palliative care utilization, racial/ethnic disparities in hospitalization outcomes among adult women with a diagnosis of metastatic breast cancer (MBC), and…
The FDA approved zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.
Martin H. Voss, MD, discusses the clinical significance of the phase 3 KEYNOTE-564 trial in clear cell renal cell carcinoma.
The FDA was expected to decide on the application of sotorasib and panitumumab for the treatment of metastatic colorectal cancer on October 17, 2024.
Lenvatinib combined with pembrolizumab could be a potential treatment for previously treated advanced B3-thymoma and thymic carcinoma. Jordi Remon Masip (Gustave Roussy, Villejuif, France) presented…
Radiology Today newsmagazine reaches 40,000 radiology professionals nationwide on a monthly basis, covering areas such as Radiology Management, Bone Densitometry, Mammography, MRI, PACS, CT, Sonography,…
Zolbetuximab wins approval for CLDN18.2-positive gastric/GEJ cancer, TTFields joins the NSCLC armamentarium, and more of this week’s top news in oncology.